JP7373512B2 - Ｔ細胞アクティベーターとして有用なナフチリジノン化合物 - Google Patents

Ｔ細胞アクティベーターとして有用なナフチリジノン化合物 Download PDF

Info

Publication number
JP7373512B2
JP7373512B2 JP2020572994A JP2020572994A JP7373512B2 JP 7373512 B2 JP7373512 B2 JP 7373512B2 JP 2020572994 A JP2020572994 A JP 2020572994A JP 2020572994 A JP2020572994 A JP 2020572994A JP 7373512 B2 JP7373512 B2 JP 7373512B2
Authority
JP
Japan
Prior art keywords
methyl
dihydro
oxo
piperazin
naphthyridine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2020572994A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021528469A (ja
JP2021528469A5 (enExample
Inventor
ルイス・エス・チュパック
ミン・ディン
ロバート・ジー・ジェントルズ
ヤージョン・フアン
スコット・ダブリュー・マーティン
アイバー・エム・マクドナルド
スティーブン・イー・マーサー
リチャード・イー・オルソン
アッペンダー・ベラパルチ
マイケル・ウィクロスキー
シャオファン・ジェン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bristol Myers Squibb Co
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of JP2021528469A publication Critical patent/JP2021528469A/ja
Publication of JP2021528469A5 publication Critical patent/JP2021528469A5/ja
Application granted granted Critical
Publication of JP7373512B2 publication Critical patent/JP7373512B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
JP2020572994A 2018-06-27 2019-06-26 Ｔ細胞アクティベーターとして有用なナフチリジノン化合物 Active JP7373512B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862690444P 2018-06-27 2018-06-27
US62/690,444 2018-06-27
PCT/US2019/039131 WO2020006016A1 (en) 2018-06-27 2019-06-26 Naphthyridinone compounds useful as t cell activators

Publications (3)

Publication Number Publication Date
JP2021528469A JP2021528469A (ja) 2021-10-21
JP2021528469A5 JP2021528469A5 (enExample) 2023-07-06
JP7373512B2 true JP7373512B2 (ja) 2023-11-02

Family

ID=67297314

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2020572994A Active JP7373512B2 (ja) 2018-06-27 2019-06-26 Ｔ細胞アクティベーターとして有用なナフチリジノン化合物

Country Status (25)

Country Link
US (1) US11866430B2 (enExample)
EP (1) EP3814347B1 (enExample)
JP (1) JP7373512B2 (enExample)
KR (1) KR102804324B1 (enExample)
CN (1) CN112585139B (enExample)
AU (1) AU2019291792B2 (enExample)
BR (1) BR112020026568A2 (enExample)
CA (1) CA3104647A1 (enExample)
CY (1) CY1126179T1 (enExample)
DK (1) DK3814347T3 (enExample)
EA (1) EA202190137A1 (enExample)
ES (1) ES2950007T3 (enExample)
FI (1) FI3814347T3 (enExample)
HR (1) HRP20230627T1 (enExample)
HU (1) HUE062412T2 (enExample)
IL (1) IL279730B2 (enExample)
LT (1) LT3814347T (enExample)
MX (1) MX2020013373A (enExample)
PL (1) PL3814347T3 (enExample)
PT (1) PT3814347T (enExample)
RS (1) RS64285B1 (enExample)
SG (1) SG11202012973RA (enExample)
SI (1) SI3814347T1 (enExample)
SM (1) SMT202300170T1 (enExample)
WO (1) WO2020006016A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2023510108A (ja) * 2019-12-19 2023-03-13 ブリストル－マイヤーズ スクイブ カンパニー Ｄｇｋ阻害剤およびチェックポイントアンタゴニストの組み合わせ

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR119821A1 (es) 2019-08-28 2022-01-12 Bristol Myers Squibb Co Compuestos de piridopirimidinonilo sustituidos útiles como activadores de células t
US20230064809A1 (en) 2019-11-28 2023-03-02 Bayer Aktiengesellschaft Substituted aminoquinolones as dgkalpha inhibitors for immune activation
US20230062100A1 (en) 2019-11-28 2023-03-02 Bayer Aktiengesellschaft Substituted aminoquinolones as dgkalpha inhibitors for immune activation
CR20220236A (es) 2019-11-28 2022-10-03 Bayer Pharma AG Aminoquinolonas sustituidas como inhibidores de dgk alfa para la activación inmune
AR120823A1 (es) 2019-12-23 2022-03-23 Bristol Myers Squibb Co Compuestos bicíclicos sustituidos útiles como activadores de células t
CA3162979A1 (en) * 2019-12-23 2021-07-01 Upender Velaparthi Substituted piperazine derivatives useful as t cell activators
BR112022012179A2 (pt) 2019-12-23 2022-09-06 Bristol Myers Squibb Co Compostos de quinazolina substituída úteis como ativadores de célula t
BR112022012204A2 (pt) * 2019-12-23 2022-09-13 Bristol Myers Squibb Co Compostos de heteroarila substituída úteis como ativadores de célula t
IL294032A (en) 2019-12-24 2022-08-01 Carna Biosciences Inc Compounds that regulate diacylglycerol kinase
CN115697980B (zh) * 2020-04-24 2025-03-21 拜耳公司 作为dgkzeta抑制剂用于免疫活化的取代的氨基噻唑
WO2021258010A1 (en) 2020-06-19 2021-12-23 Gossamer Bio Services, Inc. Oxime compounds useful as t cell activators
KR102682398B1 (ko) * 2020-11-26 2024-07-05 주식회사 엘지화학 다이아실글리세롤 키나아제 저해제로서 헤테로사이클 화합물 및 이의 용도
WO2022133083A1 (en) 2020-12-16 2022-06-23 Gossamer Bio Services, Inc. Compounds useful as t cell activators
CN117693508A (zh) 2021-03-03 2024-03-12 朱诺治疗学股份有限公司 T细胞疗法和dgk抑制剂的组合
MX2023014762A (es) * 2021-06-23 2024-01-15 Gilead Sciences Inc Compuestos moduladores de diacilglicerol quinasa.
JP7686091B2 (ja) * 2021-06-23 2025-05-30 ギリアード サイエンシーズ， インコーポレイテッド ジアシルグリセロールキナーゼ調節化合物
AU2022299051B2 (en) * 2021-06-23 2025-03-13 Gilead Sciences, Inc. Diacylglyercol kinase modulating compounds
JP7651018B2 (ja) * 2021-06-23 2025-03-25 ギリアード サイエンシーズ， インコーポレイテッド ジアシルグリセロールキナーゼ調節化合物
WO2023122777A1 (en) * 2021-12-22 2023-06-29 Gossamer Bio Services, Inc. Oxime derivatives useful as t cell activators
WO2023150186A1 (en) * 2022-02-01 2023-08-10 Arvinas Operations, Inc. Dgk targeting compounds and uses thereof
WO2023165528A1 (en) * 2022-03-01 2023-09-07 Insilico Medicine Ip Limited Diacylglycerol kinase (dgk) alpha inhibitors and uses thereof
EP4486741A4 (en) 2022-03-01 2026-04-08 Insilico Medicine Ip Ltd Diacylglycerol Kinase (DGK) Alpha Inhibitors and Their Uses
WO2023165525A1 (en) * 2022-03-01 2023-09-07 Insilico Medicine Ip Limited Diacylglycerol kinase (dgk) alpha inhibitors and uses thereof
US20250215014A1 (en) * 2022-03-31 2025-07-03 InventisBio Co., Ltd. Kinase inhibitors, preparation methods and uses thereof
US12600722B2 (en) 2022-07-18 2026-04-14 Incyte Corporation Tetracyclic compounds as DGK inhibitors
US12600723B2 (en) 2022-07-18 2026-04-14 Incyte Corporation Tetracyclic compounds as DGK inhibitors
EP4561561A2 (en) * 2022-07-29 2025-06-04 Septerna, Inc. Substituted 3,4-dihydroquinolinone inhibitors of tshr
CN119677740A (zh) 2022-08-09 2025-03-21 百时美施贵宝公司 用作t细胞活化剂的叔胺取代的双环化合物
EP4583876A1 (en) 2022-09-08 2025-07-16 Juno Therapeutics, Inc. Combination of a t cell therapy and continuous or intermittent dgk inhibitor dosing
EP4661869A1 (en) 2023-02-06 2025-12-17 Bayer Aktiengesellschaft Combinations of dgk (diacylglycerol kinase) inhibitors and immune checkpoint inhibitors and modulators
WO2025030002A2 (en) * 2023-08-02 2025-02-06 Arvinas Operations, Inc. Dgk targeting compounds and uses thereof
WO2025061020A1 (zh) * 2023-09-21 2025-03-27 楚浦创制（武汉）医药科技有限公司 苯并五元杂环衍生物及其制备方法与应用、药物组合物
WO2026006759A1 (en) 2024-06-28 2026-01-02 Arcus Biosciences, Inc. Pharmaceutical compositions, dosage forms, and methods of making and using same

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050266510A1 (en) 2004-01-08 2005-12-01 Gajewski Thomas G T cell anergy is reversed by active Ras and regulated by diacylglycerol kinase
JP2007503388A (ja) 2003-08-22 2007-02-22 アバニール・ファーマシューティカルズ マクロファージ遊走阻止因子の阻害剤としての置換ナフチリジン誘導体、およびヒト疾患の治療におけるそれらの使用
JP2016500065A (ja) 2012-11-16 2016-01-07 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツングＭｅｒｃｋ Ｐａｔｅｎｔ Ｇｅｓｅｌｌｓｃｈａｆｔ ｍｉｔ ｂｅｓｃｈｒａｅｎｋｔｅｒ Ｈａｆｔｕｎｇ キナーゼ活性のモジュレーターとしての新規複素環式誘導体
WO2017177037A1 (en) 2016-04-06 2017-10-12 University Of Virginia Patent Foundation Compositions and methods for treating cancer

Family Cites Families (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4324893A (en) 1979-04-18 1982-04-13 American Home Products Corporation 4-Amino-3-carboxy or cyano-1,2-dihydro-2-oxo-1,8-naphthyridine derivatives
UY27304A1 (es) 2001-05-24 2002-12-31 Avanir Pharmaceuticals Inhibidores del factor inhibidor de la migración de los macrófagos y métodos para su identificación
BR0312204A (pt) 2002-06-27 2005-04-26 Schering Ag Antagonista de receptor ccr5 de quinolina substituìda
GB0230018D0 (en) 2002-12-23 2003-01-29 Syngenta Ltd Fungicides
TW200418829A (en) 2003-02-14 2004-10-01 Avanir Pharmaceutics Inhibitors of macrophage migration inhibitory factor and methods for identifying the same
WO2004087880A2 (en) 2003-03-26 2004-10-14 Bayer Pharmaceuticals Corporation Compounds and their use to treat diabetes and related disorders
GB0316915D0 (en) 2003-07-18 2003-08-20 Glaxo Group Ltd Compounds
EP1660087A2 (en) 2003-07-22 2006-05-31 Janssen Pharmaceutica N.V. Quinolinone derivatives as inhibitors of c-fms kinase
TWI380996B (zh) 2004-09-17 2013-01-01 Hoffmann La Roche 抗ｏｘ４０ｌ抗體
PT2343320T (pt) 2005-03-25 2018-01-23 Gitr Inc Anticorpos anti-gitr e as suas utilizações
PL1879573T3 (pl) 2005-05-10 2013-05-31 Incyte Holdings Corp Modulatory 2,3-dioksygenazy indoloaminy i sposoby ich zastosowania
PT1907424E (pt) 2005-07-01 2015-10-09 Squibb & Sons Llc Anticorpos monoclonais humanos para o ligando 1 de morte programada (pd-l1)
US8450351B2 (en) 2005-12-20 2013-05-28 Incyte Corporation N-hydroxyamidinoheterocycles as modulators of indoleamine 2,3-dioxygenase
GB0605689D0 (en) * 2006-03-21 2006-05-03 Novartis Ag Organic compounds
JP2007308402A (ja) 2006-05-17 2007-11-29 Sumitomo Chemical Co Ltd シンナモイル化合物及びその用途
JP2007308441A (ja) 2006-05-22 2007-11-29 Sumitomo Chemical Co Ltd 含複素環化合物及びその用途
WO2008036642A2 (en) 2006-09-19 2008-03-27 Incyte Corporation N-hydroxyamidinoheterocycles as modulators of indoleamine 2,3-dioxygenase
CL2007002650A1 (es) 2006-09-19 2008-02-08 Incyte Corp Compuestos derivados de heterociclo n-hidroxiamino; composicion farmaceutica, util para tratar cancer, infecciones virales y desordenes neurodegenerativos entre otras.
EP1987839A1 (en) 2007-04-30 2008-11-05 I.N.S.E.R.M. Institut National de la Sante et de la Recherche Medicale Cytotoxic anti-LAG-3 monoclonal antibody and its use in the treatment or prevention of organ transplant rejection and autoimmune disease
US8591886B2 (en) 2007-07-12 2013-11-26 Gitr, Inc. Combination therapies employing GITR binding molecules
EP2044949A1 (en) 2007-10-05 2009-04-08 Immutep Use of recombinant lag-3 or the derivatives thereof for eliciting monocyte immune response
US10047066B2 (en) 2007-11-30 2018-08-14 Newlink Genetics Corporation IDO inhibitors
AR072999A1 (es) 2008-08-11 2010-10-06 Medarex Inc Anticuerpos humanos que se unen al gen 3 de activacion linfocitaria (lag-3) y los usos de estos
WO2010042489A2 (en) 2008-10-06 2010-04-15 Emory University Aminoquinoline derived heat shock protein 90 inhibitors, methods of preparing same, and methods for their use
EP3255060A1 (en) 2008-12-09 2017-12-13 F. Hoffmann-La Roche AG Anti-pd-l1 antibodies and their use to enhance t-cell function
US20110319416A1 (en) 2009-01-28 2011-12-29 Emory University Subunit Selective NMDA Receptor Antagonists For The Treatment Of Neurological Conditions
KR101790802B1 (ko) 2009-09-03 2017-10-27 머크 샤프 앤드 돔 코포레이션 항-ｇｉｔｒ 항체
EP2493862B1 (en) 2009-10-28 2016-10-05 Newlink Genetics Corporation Imidazole derivatives as ido inhibitors
ES2722300T3 (es) 2009-12-10 2019-08-09 Hoffmann La Roche Anticuerpos que se unen preferentemente al dominio extracelular 4 de CSF1R y su uso
EP2542256B1 (en) 2010-03-04 2019-05-22 MacroGenics, Inc. Antibodies reactive with b7-h3, immunologically active fragments thereof and uses thereof
US9169323B2 (en) 2010-03-05 2015-10-27 Hoffmann-La Roche Inc. Antibodies against human CSF-1R
JP5989547B2 (ja) 2010-03-05 2016-09-07 エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト ヒトｃｓｆ−１ｒに対する抗体及びその使用
HRP20190047T1 (hr) 2010-05-04 2019-02-22 Five Prime Therapeutics, Inc. Protutijela koja se vežu na csf1r
US9050334B2 (en) 2010-07-16 2015-06-09 Innov88 Llc MIF inhibitors and their uses
MX337040B (es) 2010-09-09 2016-02-09 Pfizer Moleculas de union a 4-1bb.
WO2012142498A2 (en) 2011-04-13 2012-10-18 Innovimmune Biotherapeutics, Inc. Mif inhibitors and their uses
NO2694640T3 (enExample) 2011-04-15 2018-03-17
JP6072771B2 (ja) 2011-04-20 2017-02-01 メディミューン，エルエルシー Ｂ７−ｈ１およびｐｄ−１に結合する抗体およびその他の分子
KR101764096B1 (ko) 2011-11-28 2017-08-02 메르크 파텐트 게엠베하 항-ｐｄ-ｌ1 항체 및 그의 용도
RU2658603C2 (ru) 2011-12-15 2018-06-21 Ф.Хоффманн-Ля Рош Аг Антитела против человеческого csf-1r и их применения
KR20140127855A (ko) 2012-02-06 2014-11-04 제넨테크, 인크. Csf1r 억제제를 사용하는 조성물 및 방법
AR089939A1 (es) 2012-02-09 2014-10-01 Glenmark Pharmaceuticals Sa COMPUESTOS BICICLICOS COMO INHIBIDORES DE mPGES-1
AR090263A1 (es) 2012-03-08 2014-10-29 Hoffmann La Roche Terapia combinada de anticuerpos contra el csf-1r humano y las utilizaciones de la misma
RU2670743C9 (ru) 2012-05-11 2018-12-19 Файв Прайм Терапьютикс, Инк. Способы лечения состояний антителами, которые связывают рецептор колониестимулирующего фактора 1 (csf1r)
UY34887A (es) 2012-07-02 2013-12-31 Bristol Myers Squibb Company Una Corporacion Del Estado De Delaware Optimización de anticuerpos que se fijan al gen de activación de linfocitos 3 (lag-3) y sus usos
CN107759690A (zh) 2012-08-31 2018-03-06 戊瑞治疗有限公司 用结合群落刺激因子1受体(csf1r)的抗体治疗病状的方法
WO2014039513A2 (en) 2012-09-04 2014-03-13 The Trustees Of The University Of Pennsylvania Inhibition of diacylglycerol kinase to augment adoptive t cell transfer
ES2898765T3 (es) 2015-04-10 2022-03-08 Araxes Pharma Llc Compuestos de quinazolina sustituidos y métodos de uso de los mismos
PT3889145T (pt) 2015-12-17 2024-04-02 Merck Patent Gmbh 8-ciano-5-piperidino-quinolinas como antagonistas de tlr7/8 e suas utilizações para tratamento de distúrbios imunitários
JOP20190086A1 (ar) * 2016-10-21 2019-04-18 Novartis Ag مشتقات نافثيريدينون جديدة واستخدامها في معالجة عدم انتظام ضربات القلب
CN110366550A (zh) 2016-12-22 2019-10-22 美国安进公司 作为用于治疗肺癌、胰腺癌或结直肠癌的KRAS G12C抑制剂的苯并异噻唑、异噻唑并[3,4-b]吡啶、喹唑啉、酞嗪、吡啶并[2,3-d]哒嗪和吡啶并[2,3-d]嘧啶衍生物
GB201700814D0 (en) 2017-01-17 2017-03-01 Liverpool School Tropical Medicine Compounds
AU2018273356B2 (en) 2017-05-22 2021-09-16 Amgen Inc. KRAS G12C inhibitors and methods of using the same
US12187687B2 (en) 2017-06-26 2025-01-07 University Of Virginia Patent Foundation Compositions and uses thereof

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2007503388A (ja) 2003-08-22 2007-02-22 アバニール・ファーマシューティカルズ マクロファージ遊走阻止因子の阻害剤としての置換ナフチリジン誘導体、およびヒト疾患の治療におけるそれらの使用
US20050266510A1 (en) 2004-01-08 2005-12-01 Gajewski Thomas G T cell anergy is reversed by active Ras and regulated by diacylglycerol kinase
JP2016500065A (ja) 2012-11-16 2016-01-07 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツングＭｅｒｃｋ Ｐａｔｅｎｔ Ｇｅｓｅｌｌｓｃｈａｆｔ ｍｉｔ ｂｅｓｃｈｒａｅｎｋｔｅｒ Ｈａｆｔｕｎｇ キナーゼ活性のモジュレーターとしての新規複素環式誘導体
WO2017177037A1 (en) 2016-04-06 2017-10-12 University Of Virginia Patent Foundation Compositions and methods for treating cancer

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2023510108A (ja) * 2019-12-19 2023-03-13 ブリストル－マイヤーズ スクイブ カンパニー Ｄｇｋ阻害剤およびチェックポイントアンタゴニストの組み合わせ

Also Published As

Publication number Publication date
SG11202012973RA (en) 2021-01-28
SMT202300170T1 (it) 2023-09-06
US11866430B2 (en) 2024-01-09
HUE062412T2 (hu) 2023-10-28
CA3104647A1 (en) 2020-01-02
IL279730A (en) 2021-03-01
US20210277004A1 (en) 2021-09-09
AU2019291792A1 (en) 2021-02-11
MX2020013373A (es) 2021-03-09
WO2020006016A1 (en) 2020-01-02
CN112585139B (zh) 2023-12-01
JP2021528469A (ja) 2021-10-21
KR102804324B1 (ko) 2025-05-08
SI3814347T1 (sl) 2023-07-31
IL279730B1 (en) 2023-08-01
PL3814347T3 (pl) 2023-07-24
BR112020026568A2 (pt) 2021-03-23
RS64285B1 (sr) 2023-07-31
DK3814347T3 (da) 2023-08-07
IL279730B2 (en) 2023-12-01
HRP20230627T1 (hr) 2023-09-29
CY1126179T1 (el) 2026-02-25
EA202190137A1 (ru) 2021-05-17
AU2019291792B2 (en) 2022-09-29
CN112585139A (zh) 2021-03-30
ES2950007T3 (es) 2023-10-04
EP3814347A1 (en) 2021-05-05
PT3814347T (pt) 2023-07-18
FI3814347T3 (fi) 2023-06-12
EP3814347B1 (en) 2023-05-03
LT3814347T (lt) 2023-07-10
KR20210024587A (ko) 2021-03-05

Similar Documents

Publication Publication Date Title
JP7373512B2 (ja) Ｔ細胞アクティベーターとして有用なナフチリジノン化合物
JP7432532B2 (ja) Ｔ細胞アクティベーターとして有用な置換ナフチリジノン化合物
JP7650864B2 (ja) Ｔ細胞アクティベーターとして有用な置換ピリドピリミジノニル化合物
JP7653440B2 (ja) Ｔ細胞アクティベーターとして有用な置換二環化合物
JP7698658B2 (ja) がん治療のための置換オキソイソインドリン化合物
JP7677976B2 (ja) Ｔ細胞アクティベーターとして有用な置換ヘテロアリール化合物
JP7653441B2 (ja) Ｔ細胞アクティベーターとして有用な置換キノリノニルピペラジン化合物
JP7712274B2 (ja) Ｔ細胞アクティベーターとして有用な置換ピペラジン誘導体
JP7023243B2 (ja) イソキノリン－３イル－カルボキサミドならびにその調製および使用の方法
CN106999450B (zh) 免疫调节剂
CN114760994A (zh) HIF-2α的抑制剂
CN115298165A (zh) 作为HIF-2α抑制剂的四氢化萘和四氢喹啉化合物
CN114206332A (zh) 2,3,5-三取代吡唑并[1,5-a]嘧啶化合物
TW201722914A (zh) 醫藥化合物
CN114667285A (zh) 抗病毒吡唑并吡啶酮化合物
WO2024260309A1 (zh) THR-β受体激动剂、其制备方法和其使用方法
JP2025528134A (ja) Ｔ細胞活性化剤として有用な置換テトラゾリル化合物
CN117157286A (zh) 经吡啶基取代的氧代异吲哚啉化合物
HK40102447A (zh) 用於治疗癌症的双环四氢氮杂䓬衍生物
JP2025528157A (ja) Ｔ細胞活性化剤として有用な第三アミン置換二環式化合物
HK40110644A (zh) 具有ent1抑制活性的大环化合物
HK40126737A (zh) 抗病毒吡唑并吡啶酮化合物
EA044500B1 (ru) Нафтиридиноновые соединения для применения в качестве активаторов t-клеток
HK40076614A (en) Inhibitors of hif-2alpha
HK40068316A (en) 2,3,5-trisubstituted pyrazolo[1,5-a]pyrimidine compounds

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220610

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20220610

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20230406

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20230516

A524 Written submission of copy of amendment under article 19 pct

Free format text: JAPANESE INTERMEDIATE CODE: A524

Effective date: 20230628

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20230926

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20231023

R150 Certificate of patent or registration of utility model

Ref document number: 7373512

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150